Phreesia, Inc. (NYSE:PHR) General Counsel Sells $230,114.06 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of Phreesia stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $27.31, for a total transaction of $230,114.06. Following the completion of the transaction, the general counsel now directly owns 146,126 shares of the company’s stock, valued at $3,990,701.06. This trade represents a 5.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Phreesia Stock Performance

PHR opened at $27.89 on Friday. The company’s 50 day moving average is $24.00 and its 200 day moving average is $23.00. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -18.98 and a beta of 0.94. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.16.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.58) EPS. On average, equities research analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PHR shares. KeyCorp boosted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, January 8th. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.00.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Versor Investments LP bought a new position in shares of Phreesia during the 3rd quarter valued at approximately $694,000. Zacks Investment Management purchased a new position in Phreesia during the third quarter valued at approximately $631,000. Sei Investments Co. boosted its position in shares of Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after purchasing an additional 95,058 shares during the period. State Street Corp raised its position in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after purchasing an additional 88,517 shares during the period. Finally, Barclays PLC lifted its stake in shares of Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after buying an additional 43,225 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.